AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00855920 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Rilonacept)
Description: Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
Study NCT04891874 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Radiation using stereotactic radiotherapy device.
Study NCT02781493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Prucalopride plus 2 L Polyethylene Glycol regimen
Description: Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
Study NCT02098265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG electrodes will be attached to the participant's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
Study NCT02098265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RecoveriX
Description: RecoveriX is a brain driven rehabilitation system for stroke patients that pairs mental activities with motor functions.
Study NCT02098265 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delay
Description: 10 week delay before intervention
Study NCT02098265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BCI-FES
Study NCT02098265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI-FES
Study NCT00687115 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weight Loss
Description: liquid diet at 50% of weight maintaining intake
Study NCT00687115 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overfeeding
Description: Overfeeding at 150% of weight maintaining intake
Study NCT00687115 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overfeeding Low Pro
Description: Overfeeding 150% of normal intake at \<5% protein
Study NCT04023110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Individually dosed carvedilol
Study NCT03656926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Cyclosporine A
Description: This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 μm
Study NCT03656926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator
Study NCT02414776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxychloroquine
Description: administration of hydroxychloroquine in combination with the current hormonal therapy
Study NCT03469518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: β-Cx plus PS plus GOS
Study NCT03469518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: β-Cx plus PS
Study NCT00788931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV LBH589
Study NCT00788931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral LBH589
Study NCT00788931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Study NCT00788931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00692614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
Study NCT03174405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.~Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)
Study NCT02781493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 2 mg Placebo plus 2 L Polyethylene Glycol regimen
Description: Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
Study NCT02650362 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI
Study NCT01767155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEZS-108 / zoptarelin doxorubicin
Description: 267 mg/m\^2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
Study NCT01767155 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin
Description: 60 mg/m\^2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
Study NCT01622790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg
Description: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
Study NCT01622790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg
Description: Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
Study NCT01622790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir 600 mg/lamivudine 300 mg
Description: This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
Study NCT00310791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (estrogen/progestin)
Description: Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
Study NCT00310791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Sugar Pill)
Description: Placebo (sugar pill)
Study NCT00310791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (DHEA)
Description: 50 mg tablet, 1 daily
Study NCT03851068 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldax Tria Aortic Valve
Description: Aortic Valve Replacement
Study NCT00959621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: ASA 100 mg once daily per os
Study NCT00959621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klexane
Description: Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
Study NCT00959621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klexane and ASA
Description: Klexane 40 mgx 1 sc and ASA 100 mg po
Study NCT01032642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: device for hysterosalpingography
Description: a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
Study NCT02141633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: echocardiogram plus albuterol
Description: participants will performed echocardiogram before and 15 minutes after inhaled albuterol
Study NCT02141633 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: airway blood flow plus albuterol
Description: participants will performed echocardiogram before and 15 minutes after inhaled albuterol
Study NCT02141633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
Study NCT02141633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
Study NCT03055325 — intervention group
Intervention type: OTHER
Intervention: Observational study of patients undergoing surgery
Description: Cognitive testing, testing of heart rate variability and collection of blood samples
Study NCT00176488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin
Description: Epirubicin (100 mg/m2) will be given on Day 1
Study NCT04251117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GNOS-PV02
Description: GNOS-PV02 delivered by intradermal injection and electroporation
Study NCT01966900 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CN54gp140 mixed with GLA-AF
Description: Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
Study NCT03932110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: omentin, visfatin
Description: diagnostic blood test
Study NCT03308877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BMI
Description: Four 45-minute, brief motivational sessions for substance use
Study NCT03308877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stadard Care (SC)
Description: Standard procedures at pretrial program + assessement
Study NCT04251117 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-9012
Description: INO-9012 delivered by intradermal injection and electroporation
Study NCT04251117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered as an intravenous (IV) infusion
Study NCT04251117 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA®2000 EP Device
Description: CELLECTRA® 2000 Device is a system indicated for use to enhance the uptake and expression of plasmid-based biologics in order to enhance vaccine efficacy.
Study NCT03308877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stadard Care (SC)
Description: Standard procedures at pretrial program + assessement
Study NCT04258397 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone vs. matching placebo
Study NCT04258397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: matching placebo
Study NCT01877434 — intervention group
Intervention type: PROCEDURE
Intervention: Reversed shoulder arthroplasty
Study NCT02322398 — intervention group
Intervention type: DRUG
Intervention: rFSH plus rLH
Description: 150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
Study NCT00176488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
Study NCT01980836 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine
Study NCT02643615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEP under TIVA
Description: Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study NCT02322398 — intervention group
Intervention type: DRUG
Intervention: hMG
Description: 150-300 IU/d hMG
Study NCT00533195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Methoxypsoralen
Description: 1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
Study NCT00533195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA1 phototherapy
Description: Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.~No maintenance therapy except emollients.
Study NCT00272467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: 1. Brand name: Mucosta® Tab.~2. Generic name: Rebamipide.~3. Chemical name:~   (±)-2-(4-chlorobenzoylamino)-3-\[2(1H)-quinolinon-4-yl\]propionic acid.~4. Formulation: Tablet (White, film-coated tablet).~5. Strength: One tablet contains rebamipide 100mg.~6. Storage condition: 15℃\~25℃.~7. Manufacturer: Korea Otsuka Pharmaceuticals
Study NCT00272467 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: 1. Brand name: Losec® Cap.~2. Generic name: Omeprazole.~3. Chemical name:~5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃\~25℃. 7) Manufacturer: AstraZenaca Korea.
Study NCT02643615 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VEP under balanced anesth.
Description: Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study NCT02860169 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Participants self-administered questionnaire and assessment
Description: Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
Study NCT02860169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participants self-administered questionnaire and assessment
Description: Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
Study NCT02000050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: FOLFOX4
Study NCT02000050 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Tomotherapy
Description: Tomotherapy
Study NCT02000050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME (Total Mesorectal Excision)
Description: TME (Total Mesorectal Excision)
Study NCT03932032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Treatment
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in social anxiety.
Study NCT03932032 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Neutral Control Task
Description: At each of eight sessions, participants complete 160 computer administered trials wherein a pair of neutral stimuli is presented simultaneously and then followed immediately by a probe. NCT matches ABMT on duration, format, and number of trials, but does not engage attention to social threat and does not train attention.
Study NCT02643615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study NCT02643615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
Study NCT01611116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium chloride solution 0.9%
Description: intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
Study NCT01611116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
Study NCT04526106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLY-4008
Description: RLY-4008 is an oral inhibitor of FGFR2
Study NCT03435796 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Gene-modified (GM) T cell therapy
Description: No investigational product will be administered
Study NCT03789435 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Questionnaire
Description: A questionnaire from which the session dedicated to the evaluation of the stump pain, the phantom limb and the sensation of the phantom limb has been extracted will be administered: this is the Prosthetic Evaluation Questionnaire (PEQ) validated in Italian by Ferrero et al. 2005.~In the questionnaire sent to patients will be asked also for anthropometric data (weight, height) in addition to the characteristics of the worn prosthesis and if they have followed a period of rehabilitation.The time of use of the prosthesis will be evaluated through the Houghton Scale of Prosthetic Use in People with Lower- Extremity Amputations (19)
Study NCT04588064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI PET/CT scan
Description: Each subject receives a single intravenous injection of 68Ga-FAPI, and undergo PET/CT imaging within the specified time.
Study NCT04568603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islatravir
Description: ISL 30 mg x 2 (60 mg total) capsules taken by mouth.
Study NCT03731572 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power Training
Description: Hip abductor-adductor resistance exercises at maximum execution speed
Study NCT03731572 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: Hip abductor-adductor resistance exercises at reduced execution speed
Study NCT00713492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: human laboratory alcohol consumption.
Study NCT04625686 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mental Health Treatment
Description: Treatment of suicidal ideation
Study NCT05598125 — intervention group
Intervention type: DEVICE
Intervention: electronic cigarette (e-cigarette)
Study NCT05598125 — intervention group
Intervention type: DEVICE
Intervention: conventional tobacco cigarette
Study NCT04086693 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV dressing
Description: Polyurethane and clear tape dressing used to secure peripheral IV
Study NCT04086693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard IV dressing plus a tissue adhesive peripheral IV securement device
Description: Polyurethane dressing with clear tape plus a tissue adhesive peripheral IV securement device used to secure peripheral IV
Study NCT03713398 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: T4C-SMI
Description: T4C-SMI entails a 25-session, manualized intervention that is delivered in a closed-group format at least twice a week over a three-month period. The intervention curriculum includes three modules: nine sessions on social skills training, five sessions on cognitive restructuring activities, and ten sessions on problem-solving methods. Participants assigned to T4C-SMI receive this intervention in addition to any other prison mental health services that they are otherwise eligible to receive during their incarceration.
Study NCT00837265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balugrastim
Description: Balugrastim (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) will be administered per dose and schedule specified in the arm description.
Study NCT03863587 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLX12
Description: healthy volunters receive HLX12 (8mg/kg) once
Study NCT03863587 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cyramza (Ramucirumab)
Description: healthy volunters receive Cyramza (Ramucirumab) 8mg/kg once
Study NCT02307396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine